Using N-acetylcysteine to prevent mouth sores in head and neck cancer patients undergoing radiation therapy
Official title: Clinical Study Evaluating the Efficacy and Safety of N-acetylcysteine in Preventing Radiotherapy-Induced Oral Mucositis in Head and Neck Cancer Patients.
Run by Mansoura University · NCT06354712 · Data updated 2026-11-12
This study is testing if N-acetylcysteine can help prevent painful mouth sores in adults with head and neck cancer who are getting radiation treatment.
Quick facts
| Phase | Phase 2 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years to 80 Years |
| Sex | All |
| Enrollment | 50 (estimated) |
| Sponsor | Mansoura University Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Al Mansurah) |
| Status | Recruiting |
| Started | April 4, 2024 |
| Main results expected | March 1, 2025 |
| Study ends | March 1, 2025 |
| Registry record updated | January 15, 2025 |
| Trial ID | NCT06354712 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are adults over 18 years old with squamous cell carcinoma of the head and neck who are about to start curative radiotherapy.
✕Probably not a fit
Patients who have previously undergone chemotherapy or radiotherapy, or those with systemic infections or severe liver or kidney disorders, may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This clinical trial is designed to evaluate the effectiveness of N-acetylcysteine in preventing oral mucositis, a painful condition that can occur in patients receiving radiotherapy for head and neck cancer. The study will be a prospective, randomized, controlled trial conducted at Mansoura University Hospital, where participants will receive either N-acetylcysteine alongside standard care or standard care alone. The trial aims to determine if N-acetylcysteine can reduce the incidence and severity of oral mucositis in this patient population. Eligible participants include adults diagnosed with squamous cell carcinoma of the head and neck who are scheduled for curative radiotherapy.
Why it matters
Potential benefit: If successful, this treatment could significantly reduce the incidence of painful oral mucositis in patients undergoing radiotherapy for head and neck cancer.
How similar studies have gone: While there have been studies exploring various interventions for oral mucositis, the specific use of N-acetylcysteine in this context is relatively novel and has not been extensively tested.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Adults \>18 years diagnosed with squamous cell carcinoma of the head and neck scheduled to receive curative radiotherapy (Primary or postoperative) of at least 50 Gy with or without concurrent chemotherapy. 2. Individuals with healthy mucosa. 3. Adequate bone marrow function (Hemoglobin level ≥10 g/dL, platelet count ≥75 × 103/microliter, and absolute neutrophil count ≥1.5 × 103/microliter). 4. Patients with ECOG performance ≤2 Exclusion Criteria: 1. History of chemotherapy or radiotherapy. 2. Signs of systemic infections. 3. Pregnant and lactating women. 4. Individuals receiving systemic analgesics. 5. Liver disorders and renal failure with eGFR \<30 ml/min/1.73m2 (by the MDRD equation). 6. Inability to follow instructions and complete the questionnaires.
Where it's running
-
Clinical Oncology and Nuclear Medicine of Mansoura University Hospital
Al Mansurah, Egypt Recruiting
Study contacts
- Principal investigator: Mohamed el-Husseiny shams, Professor — Department of Clinical pharmacy and Pharmacy practice, Faculty of Pharmacy, Mansoura University
- Study coordinator: Reem Abou-Elezz, BSc
- Email: reemabouelezz@mans.edu.eg
- Phone: +201065396455
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Taurine to help prevent and treat mouth ulcers from radiation in NPC
This study tests whether taurine can help prevent and lessen severe radiation-induced oral mucositis in adults with newly diagnosed nasopharyngeal carcinoma receiving radiotherapy.
-
Copaiba Mouthwash with Low-Level Laser Therapy to Prevent Mouth Sores After Stem Cell Transplant
This phase 2 trial tests whether a copaíba-based mouthwash, used four times daily, can help prevent oral mucositis in patients undergoing autologous hematopoietic stem cell transplantation.
-
Houyanqing oral liquid to prevent and treat radiation mouth sores in nasopharyngeal cancer
This phase 3 trial will test whether adding Houyanqing oral liquid to standard care can prevent or lessen radiation-caused mouth sores in adults receiving radiotherapy for nasopharyngeal cancer.
-
TCM oral liquid plus herbal mouthwash for radiation‑caused mouth sores in head and neck cancer
This study will test whether taking a Qingying oral liquid and using a modified Da Huang‑Huang Lian Xiexin mouthwash can reduce how often, how long, and how severe radiation‑induced mouth sores are in adults receiving radiotherapy for head and neck cancer.
-
Rice bran for radiation-related mouth sores in head and neck cancer
This trial will try rice bran supplements during radiation to see if adults with head and neck cancer have fewer or less severe mouth sores.
-
Taurine to prevent radiation-induced mouth sores and skin reactions
This trial will test whether taking a daily taurine granule before each radiotherapy session reduces radiation-induced oral mucositis and radiodermatitis in adults receiving postoperative radiotherapy for oral/oropharyngeal cancer.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.